Physiological Effect: Increased Hematopoietic Stem Cell Mobilization
✉ Email this page to a colleague
Drugs with Physiological Effect: Increased Hematopoietic Stem Cell Mobilization
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Msn | PLERIXAFOR | plerixafor | SOLUTION;SUBCUTANEOUS | 211901-001 | Jul 24, 2023 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Teva Pharms Usa Inc | PLERIXAFOR | plerixafor | SOLUTION;SUBCUTANEOUS | 205197-001 | Jul 24, 2023 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Dr Reddys | PLERIXAFOR | plerixafor | SOLUTION;SUBCUTANEOUS | 205182-001 | Jul 24, 2023 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Eugia Pharma | PLERIXAFOR | plerixafor | SOLUTION;SUBCUTANEOUS | 213672-001 | Jul 24, 2023 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |